[HTML][HTML] Nano-based approved pharmaceuticals for cancer treatment: present and future challenges
F Rodríguez, P Caruana, N De la Fuente, P Español… - Biomolecules, 2022 - mdpi.com
Cancer is one of the main causes of death worldwide. To date, and despite the advances in
conventional treatment options, therapy in cancer is still far from optimal due to the non …
conventional treatment options, therapy in cancer is still far from optimal due to the non …
[HTML][HTML] Systemic therapy for early-stage breast cancer: learning from the past to build the future
E Agostinetto, J Gligorov, M Piccart - Nature Reviews Clinical Oncology, 2022 - nature.com
The treatment of breast cancer has improved dramatically over the past century, from a
strictly surgical approach to a coordinated one, including local and systemic therapies …
strictly surgical approach to a coordinated one, including local and systemic therapies …
[HTML][HTML] Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast …
L Gianni, CS Huang, D Egle, B Bermejo, C Zamagni… - Annals of …, 2022 - Elsevier
Background High-risk triple-negative breast cancers (TNBCs) are characterized by poor
prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy …
prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy …
[HTML][HTML] Engineering patient-specific cancer immunotherapies
Research into the immunological processes implicated in cancer has yielded a basis for the
range of immunotherapies that are now considered the fourth pillar of cancer treatment …
range of immunotherapies that are now considered the fourth pillar of cancer treatment …
FDG-PET/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis of diagnostic accuracy …
S Sheikhbahaei, TJ Trahan, J Xiao, M Taghipour… - The …, 2016 - academic.oup.com
Introduction. This study compared the diagnostic test accuracy of magnetic resonance
imaging (MRI) with that of 18F-fluoro-2-glucose-positron emission tomography/computed …
imaging (MRI) with that of 18F-fluoro-2-glucose-positron emission tomography/computed …
[HTML][HTML] Triple negative breast cancer: looking for the missing link between biology and treatments
G Palma, G Frasci, A Chirico, E Esposito, C Siani… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract The so called “Triple Negative Breast Cancer”(TNBC) represents approximately 15-
20% of breast cancers. This acronym simply means that the tumour does not express …
20% of breast cancers. This acronym simply means that the tumour does not express …
Small molecule HDAC inhibitors: Promising agents for breast cancer treatment
M Huang, J Zhang, C Yan, X Li, J Zhang, R Ling - Bioorganic chemistry, 2019 - Elsevier
Breast cancer, a heterogeneous disease, is the most frequently diagnosed cancer and the
second leading cause of cancer-related death among women worldwide. Recently …
second leading cause of cancer-related death among women worldwide. Recently …
[HTML][HTML] Updated results of TBCRC026: phase II trial correlating standardized uptake value with pathological complete response to pertuzumab and trastuzumab in …
PURPOSE Predictive biomarkers to identify patients with human epidermal growth factor
receptor 2 (HER2)–positive breast cancer who may benefit from targeted therapy alone are …
receptor 2 (HER2)–positive breast cancer who may benefit from targeted therapy alone are …
The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and …
F Tian, G Shen, Y Deng, W Diao, Z Jia - European Radiology, 2017 - Springer
Objectives The aim of this meta-analysis was to evaluate the accuracy of 18 F-FDG PET/CT
in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast …
in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast …
[HTML][HTML] Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis
Y Zong, J Wu, K Shen - Oncotarget, 2017 - ncbi.nlm.nih.gov
Background The value of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in
neoadjuvant systemic therapy for breast cancer remains uncertain. Methods Both electronic …
neoadjuvant systemic therapy for breast cancer remains uncertain. Methods Both electronic …